The abstract is read at the publisher; the summary is JClub's.
ECMM and MSGERC are revising the 2008 MSG/EORTC consensus trial criteria for invasive candidiasis because evolving Candida epidemiology and newer antifungal agents require updated, standardized outcome adjudication.
- Why it matters: Current efficacy assessments in invasive candidiasis trials still rely on older consensus definitions, which may not adequately reflect advances in clinical mycology, shifts toward non-albicans Candida, or responses to newer regimens.
- What they did: The groups decided to revise the criteria used for future studies, building on the 2008 MSG/EORTC definitions originally presented by Segal et al and used by investigators and regulatory agencies.
- The result: Updated endpoints are intended to improve standardized adjudication of patient outcomes and better capture therapeutic responses to modern interventions and newer antifungal therapies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.